OCT 07, 2016 05:41 AM PDT

Scientists Find an Epigenetic Switch for Cancer's Immortality

WRITTEN BY: Xuan Pham

If you could microscopically dissect a tumor, you’d find a diverse collection of cells. While all the cells have gone rogue in one way or another, some are highly active, constantly dividing, and some appear to be more dormant. What keeps the active cells in their “youthful” state, and how can we exhaust these cells to stop tumors from growing?
 

Image credit: Pixabay.com

Scientists at the Francis Crick Institute now believe the answer to a cancer cell’s immortality involves a linker histone protein known as H1.0.
 
“Every cancer is different, but even within the same tumor cells are highly diverse, and only some of them are truly immortal and drive tumor growth,” said Paola Scaffidi, the senior author of the study. As such, Scaffidi and her team asked what mechanism allowed the cancer cells to keep growing. If we knew this answer, she reasoned, we could exploit it in the form of new anticancer treatments.
 
The team analyzed tumor samples from mice, honing in on any pattern that differed between cells that were seemingly immortal to their more quiescent counterpart. They found that the histone protein H1.0 was unusually low in cells that were trapped in the “youthful” state.
 
Histone proteins act like a spool around which the DNA helix is wound. The degree to which DNA is wrapped on the histones determines the ease of gene transcription, and thus, gene expression. That is, loosely wrapped DNA is associated with increased gene expression, and vice versa.
 
In normal cells, Scaffidi and her team found that H1.0 expression was high, which meant DNA was coiled much tighter. By contrast, cancer cells that lack H1.0 seemed to have DNA uncoiled at certain regions, which then allowed genes involved in proliferation to be systematically activated. H1.0 seemed to act as a genetic switch for cancer cells’ immortality.
 
If it can be turned on erroneously in cancer, can we turn it off to treat cancer? As it turns out, cancer cells have low H1.0 because of a molecular tag on the gene that encodes this protein. We’re not certain of how exactly this tag stops the H1.0 protein being made,” says Scaffidi. But, what the team does know is that targeting the tag to turn on H1.0 levels can reverse the cells’ propensity for eternal youth.
 


“If we can find a way to reactivate H1.0 in cancer patients, then we might be able to stop tumour growth,” Scaffidi said. “We’re looking for molecules which can boost H1.0 that are already used in patients, so we know they’re safe.
 
"This research opens up the possibility of one day turning harmful tumors into benign ones by reverting cancer cells back to a finite lifespan, which would eventually cause the tumor to stop growing. Importantly, we've shown that patients whose tumors had low levels of H1.0 tend to do worse and that this was apparent across a range of cancers,” Scaffidi said. "We now know where to start looking for drugs that work by revoking cancer cells' immortality, rather than just killing them off."
 
Additional sources: Cancer Research UK, MNT, Medical Research interview with Paola Scaffidi

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 07, 2018
Clinical & Molecular DX
JUN 07, 2018
Digital Screening Vital for Detecting Breast Cancer
A combination of two digital techniques could be the best way to diagnose breast cancer. In a new study, scientists show how combining a technique called t...
JUN 16, 2018
Clinical & Molecular DX
JUN 16, 2018
Nanoparticles Deliver "Theranostics" for Cancer Patients
New technology combing therapeutic agents and diagnostics (theranostics) can be used to deliver drugs to cancer cells. From the Moscow Institute of Physics...
JUN 26, 2018
Cancer
JUN 26, 2018
Five "-omics" Fields Introduced
An introduction to genomics, transcriptomics, proteomics, epigenomics, and metabolomics....
JUL 18, 2018
Immunology
JUL 18, 2018
Immunotherapy Increases Survival of Melanoma Brain Metastases Patients
Use of Checkpoint Blockade Immunotherapy increases survival rates in Melanoma Brain Metastases patients, with a 4-year survival rate increase from 11.1% to 28.1%...
JUL 31, 2018
Cancer
JUL 31, 2018
Can Medicine Prevent Cisplatin-associated Hearing Loss for Pediatric Cancer Patients?
Researchers have determined that sodium thiosulfate's antioxidant properties can prevent hearing loss in pediatric cancer patients being treated with Cisplatin....
AUG 10, 2018
Immunology
AUG 10, 2018
Cancer Cell 'Drones' Battle Immune System
Cancer cells release PD-L1 containing exosomes that circulate in the blood and stop T cells before they can reach tumors....
Loading Comments...